Clinical Trial Update: Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of vorinostat in primary cutaneous T-cell lymphoma was terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: University of Washington | Conditions: Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II | Phase 2 | Status: TERMINATED | Results posted: 2014-12-15